Skip to main content
TipRanks
Go Ultimate75% OFF

Monte Rosa Therapeutics (GLUE) Ratios

408 Followers

Monte Rosa Therapeutics Ratios

GLUE's free cash flow for Q3 2026 was $-42.54M. For the 2026 fiscal year, GLUE's free cash flow was decreased by $-1.56M and operating cash flow was $-40.98M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio6.122.405.0710.7920.96
Quick Ratio6.122.405.0710.7920.96
Cash Ratio2.021.432.752.1520.80
Solvency Ratio-0.14-0.30-1.04-1.48-3.82
Operating Cash Flow Ratio-0.360.27-0.94-3.62-3.57
Short-Term Operating Cash Flow Coverage0.000.000.000.000.00
Net Current Asset Value$ 177.58M$ 161.64M$ 111.71M$ 204.91M$ 329.85M
Leverage Ratios
Debt-to-Assets Ratio0.090.100.150.140.00
Debt-to-Equity Ratio0.170.190.260.170.00
Debt-to-Capital Ratio0.140.160.200.150.00
Long-Term Debt-to-Capital Ratio0.130.000.000.000.00
Financial Leverage Ratio1.931.971.691.261.05
Debt Service Coverage Ratio0.000.000.00-28.860.00
Interest Coverage Ratio0.000.000.00-29.860.00
Debt to Market Cap0.030.000.000.000.00
Interest Debt Per Share0.600.580.901.070.00
Net Debt to EBITDA2.892.930.600.074.89
Profitability Margins
Gross Profit Margin93.24%89.26%0.00%0.00%0.00%
EBIT Margin-32.12%-92.74%0.00%0.00%0.00%
EBITDA Margin-25.36%-82.00%0.00%0.00%0.00%
Operating Profit Margin-43.83%-107.26%0.00%0.00%0.00%
Pretax Profit Margin-32.12%-92.74%0.00%0.00%0.00%
Net Profit Margin-31.23%-96.14%0.00%0.00%0.00%
Continuous Operations Profit Margin-31.23%-96.14%0.00%0.00%0.00%
Net Income Per EBT97.24%103.66%100.25%100.00%100.00%
EBT Per EBIT73.28%86.46%94.21%96.54%101.48%
Return on Assets (ROA)-8.61%-16.57%-44.56%-31.69%-20.19%
Return on Equity (ROE)-16.57%-32.61%-75.51%-39.98%-21.28%
Return on Capital Employed (ROCE)-14.10%-28.78%-55.73%-35.47%-20.84%
Return on Invested Capital (ROIC)-13.56%-28.41%-55.05%-35.13%-20.84%
Return on Tangible Assets-8.61%-16.57%-44.56%-31.69%-20.19%
Earnings Yield-3.76%-14.17%-46.61%-30.19%-7.78%
Efficiency Ratios
Receivables Turnover26.89437.120.000.000.00
Payables Turnover2.350.470.560.000.00
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover2.461.340.000.000.00
Asset Turnover0.280.170.000.000.00
Working Capital Turnover Ratio0.450.370.000.000.00
Cash Conversion Cycle-141.49-772.90-654.210.000.00
Days of Sales Outstanding13.580.840.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding155.07773.73654.210.000.00
Operating Cycle13.580.840.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-0.350.57-0.85-1.96-1.28
Free Cash Flow Per Share-0.420.51-1.22-2.23-1.48
Dividend Paid and CapEx Coverage Ratio-4.8510.53-2.30-7.16-6.10
Capital Expenditure Coverage Ratio-4.8510.53-2.30-7.16-6.10
Operating Cash Flow Coverage Ratio-0.580.98-0.95-1.970.00
Operating Cash Flow to Sales Ratio-0.180.560.000.000.00
Free Cash Flow Yield-2.68%7.41%-21.64%-29.32%-7.27%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-26.58-7.08-2.15-3.31-12.85
Price-to-Sales (P/S) Ratio8.316.780.000.000.00
Price-to-Book (P/B) Ratio4.412.301.621.322.73
Price-to-Free Cash Flow (P/FCF) Ratio-37.3713.50-4.62-3.41-13.75
Price-to-Operating Cash Flow Ratio-45.0812.21-6.63-3.89-16.01
Price-to-Earnings Growth (PEG) Ratio0.670.11-0.15-0.07-0.14
Enterprise Value Multiple-29.87-5.34-1.52-3.24-8.54
Enterprise Value937.03M331.40M208.33M351.49M604.19M
EV to EBITDA-29.87-5.34-1.52-3.24-8.54
EV to Sales7.584.380.000.000.00
EV to Free Cash Flow-34.088.72-3.32-3.34-8.74
EV to Operating Cash Flow-41.107.89-4.76-3.80-10.18
Tangible Book Value Per Share3.563.023.495.757.47
Shareholders’ Equity Per Share3.563.023.495.757.47
Tax and Other Ratios
Effective Tax Rate0.03-0.04-0.000.000.00
Revenue Per Share1.891.020.000.000.00
Net Income Per Share-0.59-0.98-2.63-2.30-1.59
Tax Burden0.971.041.001.001.00
Interest Burden1.001.000.940.971.01
Research & Development to Revenue1.141.610.000.000.00
SG&A to Revenue0.290.470.000.000.00
Stock-Based Compensation to Revenue0.150.240.000.000.00
Income Quality0.59-0.580.320.850.80

Currency in USD